Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Alcon Research |
---|---|
Information provided by: | Alcon Research |
ClinicalTrials.gov Identifier: | NCT00346957 |
The purpose of the study was to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.
Condition | Intervention | Phase |
---|---|---|
AMD |
Drug: anecortave acetate |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration |
Estimated Enrollment: | 128 |
Study Start Date: | April 1999 |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: - Ages 50 years and over
Study ID Numbers: | C-98-03 |
Study First Received: | June 28, 2006 |
Last Updated: | June 30, 2006 |
ClinicalTrials.gov Identifier: | NCT00346957 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Eye Diseases Retinal Degeneration Macular Degeneration Retinal Diseases |
Eye Diseases Retinal Degeneration Macular Degeneration Retinal Diseases |